Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab plus Pembrolizumab in Advanced STS
NCT03126591Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2017
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of olaratumab in soft tissue sarcoma (STS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities. Started Jul 2017; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03126591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126591.